IL146631A0 - Diagnostics and therapeutics for cardiovascular disorders - Google Patents

Diagnostics and therapeutics for cardiovascular disorders

Info

Publication number
IL146631A0
IL146631A0 IL14663100A IL14663100A IL146631A0 IL 146631 A0 IL146631 A0 IL 146631A0 IL 14663100 A IL14663100 A IL 14663100A IL 14663100 A IL14663100 A IL 14663100A IL 146631 A0 IL146631 A0 IL 146631A0
Authority
IL
Israel
Prior art keywords
therapeutics
diagnostics
cardiovascular disorders
cardiovascular
disorders
Prior art date
Application number
IL14663100A
Other languages
English (en)
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of IL146631A0 publication Critical patent/IL146631A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/912—Absidia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
IL14663100A 1999-05-26 2000-05-26 Diagnostics and therapeutics for cardiovascular disorders IL146631A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32039599A 1999-05-26 1999-05-26
US09/431,352 US6524795B1 (en) 1997-03-10 1999-11-01 Diagnostics for cardiovascular disorders
PCT/US2000/014775 WO2000072015A2 (en) 1999-05-26 2000-05-26 Diagnostics and therapeutics for cardiovascular disorders

Publications (1)

Publication Number Publication Date
IL146631A0 true IL146631A0 (en) 2002-07-25

Family

ID=26982474

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14663100A IL146631A0 (en) 1999-05-26 2000-05-26 Diagnostics and therapeutics for cardiovascular disorders

Country Status (10)

Country Link
US (2) US6524795B1 (de)
EP (2) EP1192279B1 (de)
JP (1) JP2003500071A (de)
AT (1) ATE407221T1 (de)
AU (1) AU780318B2 (de)
CA (1) CA2374916C (de)
DE (1) DE60040150D1 (de)
ES (1) ES2313894T3 (de)
IL (1) IL146631A0 (de)
WO (1) WO2000072015A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US7820383B2 (en) * 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6291180B1 (en) * 1999-09-29 2001-09-18 American Registry Of Pathology Ultrasound-mediated high-speed biological reaction and tissue processing
WO2002000933A2 (en) * 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US20060032508A1 (en) * 2000-12-20 2006-02-16 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20050154407A1 (en) * 2000-12-20 2005-07-14 Fox Hollow Technologies, Inc. Method of evaluating drug efficacy for treating atherosclerosis
JP2004524045A (ja) * 2001-05-01 2004-08-12 カミル，ゲルハルト 醸造への流動層技術の応用
CA2450809A1 (en) * 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
EP1463745A4 (de) * 2001-11-19 2007-11-07 Interleukin Genetics Inc Sich auf die transkription sowie die anfälligkeit gegenüber entzündungs- und infektionskrankheiten auswirkende funktionspolymorphismen des interleukin-1-locus
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
KR100924468B1 (ko) * 2002-01-25 2009-11-03 인터레우킨 제네틱스, 인코포레이티드 Ｉｌ-1 유전자 집단 및 관련된 염증성 다형성과 일배체형
US20040148013A1 (en) * 2002-04-18 2004-07-29 Epstein Stephen E Stent-based delivery statins to prevent restenosis
US20030220556A1 (en) * 2002-05-20 2003-11-27 Vespro Ltd. Method, system and device for tissue characterization
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
CN100453650C (zh) * 2002-09-30 2009-01-21 诺瓦提斯公司 预测免疫抑制治疗期间胆固醇升高的方法
US6979294B1 (en) * 2002-12-13 2005-12-27 California Institute Of Technology Split-screen display system and standardized methods for ultrasound image acquisition and processing for improved measurements of vascular structures
US20050108045A1 (en) * 2003-11-17 2005-05-19 Jiao Gong Method of network hospital of reclassification of diseases that have been made a diagnosis
US20050287559A1 (en) * 2004-05-07 2005-12-29 Applera Corporation Genetic polymorphisms associated with vascular, methods of detection and uses thereof
US8034553B2 (en) * 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
WO2006093973A2 (en) * 2005-02-28 2006-09-08 University Of Massachusetts Biomarkers of vulnerable a therosclerotic plaques and methods of use
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US20060293709A1 (en) * 2005-06-24 2006-12-28 Bojarski Raymond A Tissue repair device
US8187817B2 (en) * 2005-08-02 2012-05-29 Xbiotech, Inc. Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies
WO2007050794A2 (en) * 2005-10-25 2007-05-03 Interleuken Genetics, Inc. The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
EP2089538B1 (de) * 2006-11-15 2013-08-21 Interleukin Genetics, Inc. Il-1-gen-cluster und insulinresistenz: assoziierte polymorphismen und haplotypen sowie verwendungsverfahren dafür
US20110245283A1 (en) * 2009-12-21 2011-10-06 Murata Glen H Methods for predicting the response to statins
US8906613B2 (en) * 2012-02-14 2014-12-09 Lasse Folkersen Method and kit for performing profiling of endarterectomy patients
RU2557916C1 (ru) * 2013-12-27 2015-07-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики окклюзирующих поражений сосудов у пациентов с сердечно-сосудистыми заболеваниями
WO2016054079A1 (en) 2014-09-29 2016-04-07 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
US10894985B2 (en) 2016-01-12 2021-01-19 Sitokine Limited Methods for predicting response to treatment
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US20220249660A1 (en) 2019-06-06 2022-08-11 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110920A (en) 1982-01-22 1992-05-05 Cetus Corporation HLA typing method and DNA probes used therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4623619A (en) 1982-03-03 1986-11-18 Nordisk Insulinlaboratorium Method for the determination of liability in human individuals to develop atherosclerosis
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4833080A (en) 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5268267A (en) 1987-08-21 1993-12-07 The General Hospital Corporation Method for diagnosing small cell carcinoma
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
GB9301453D0 (en) 1993-01-26 1993-03-17 Clonit Spa Nucleotide proves
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
US5686246A (en) * 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5942390A (en) 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6720141B1 (en) * 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
AU769949B2 (en) * 1998-04-21 2004-02-12 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
ES2311459T3 (es) * 1999-05-24 2009-02-16 Interleukin Genetics Inc Diagnostico de restenosis.

Also Published As

Publication number Publication date
AU5448000A (en) 2000-12-12
EP1192279B1 (de) 2008-09-03
US20030175764A1 (en) 2003-09-18
EP2071040A3 (de) 2009-06-24
JP2003500071A (ja) 2003-01-07
DE60040150D1 (de) 2008-10-16
EP2071040A2 (de) 2009-06-17
ES2313894T3 (es) 2009-03-16
WO2000072015A2 (en) 2000-11-30
CA2374916C (en) 2011-11-01
AU780318B2 (en) 2005-03-17
ATE407221T1 (de) 2008-09-15
US6524795B1 (en) 2003-02-25
CA2374916A1 (en) 2000-11-30
WO2000072015A3 (en) 2002-02-07
EP1192279A2 (de) 2002-04-03

Similar Documents

Publication Publication Date Title
IL146631A0 (en) Diagnostics and therapeutics for cardiovascular disorders
AU6110301A (en) Diagnostics and therapeutics for macular degeneration-related disorders
HK1112941A1 (en) Use of a33 antigens and jam-it a33
HK1069767A1 (en) Methods for inhibiting ocular processes
DE69939396D1 (de) Verfahren für das ausdehnen des gebrauches des sip protokolls
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
WO2000052479A3 (en) Diagnostics and therapeutics for drusen associated ocular disorders
EP1163515A4 (de) Therapeutische und diagnostische mittel für krankheiter mit gestörter glukose-tolerenz
ATE290859T1 (de) Indanderivate für antipsychotische mittel
MXPA02002251A (es) Diagnosticos y terapeuticos para osteoporosis.
DE60227517D1 (de) Verfahren zur herstellung von 10,11 dihydro 10 hydroxy 5h-dibenz/b,f/azepin-5-carbonsäureamid und 10,11 dihydro 10 oxo-5h-dibenz/b,f/azepin-5 carbonsäureamid
HK1042523A1 (zh) 青光眼和有關疾病的核酸、工具和其診斷、預後和治療的方法
EP1019092A4 (de) Therapeutische und diagnostische mittel für krankheiten mit gestörter glukose-toleranz
ZA973156B (en) Process for the production of enantiomerically-pure azetidine-2-carboxylic acid.
AU2002249983A1 (en) Compositions and methods for diagnosis of neuropsychiatric disorders
ATE258176T1 (de) Neue azabicyclo derivate und ihre verwendung
NO990450D0 (no) Behandling av sinnslidelser
AU3019201A (en) Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives
WO2004016640A3 (en) 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
TWI245756B (en) Improved process for the preparation of 1,3-substituted indenes
DE60030270D1 (de) Fettsaure analoge zur diagnose von kranzarterie erkrankungen
WO2000071081A3 (en) Methods of diagnosis and treatment of meniere disease
WO2003106385A3 (en) METHOD FOR SCREENING FUNGITOXIC COMPOUNDS